Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma

Journal of Allergy and Clinical Immunology

Volumn 118, Issue 3, 2006, Pages 574-581

  Marceau, Claudine ^a   Lemière, Catherine ^b,c   Berbiche, Djamal ^a   Perreault, Sylvie ^a   Blais, Lucie ^a,c,d  

^a Faculty of Pharmacy   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Centre de Recherche Hopital Du Sacre Coeur de Montreal   (Canada)

^d NONE

Author keywords

adherence; Asthma; combination therapy; concurrent therapy; effectiveness; persistence

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; LONG ACTING DRUG; SALMETEROL; SHORT ACTING DRUG;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INHALER; KAPLAN MEIER METHOD; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POISSON DISTRIBUTION; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; THERAPY EFFECT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ASTHMA; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33748074436     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.06.034     Document Type: Article

References (35)

1. Global Initiative for Asthma. National Institute of Health. National Heart, Lung and Blood Institute, WHO. 2003 GINA Report. Available at: http://www.ginasthma.com. Accessed August 4, 2006.
2. Lemière C., Bai T., Balter M., Bayliff C., Becker A., Boulet L.P., et al., on behalf of the Canadian Adult Consensus Group of the Canadian Thoracic Society. Adult Asthma Consensus Guidelines Update 2003. Can Respir J 11 suppl A (2004) 9A-18A
3. Barnes P.J. Scientific rationale for inhaled combination therapy with long acting B2-agonists and corticosteroids. Eur Respir J 19 (2002) 182-191
4. NAEPP Coordinating Committee. National Asthma Education and Prevention Program Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics-2002. J Allergy Clin Immunol 11 (2002) S141-S219
5. Myo S., Zhu X., Myou S., Meliton A.Y., Liu J., Boetticher E., et al. Additive blockade of b2-integrin adhesion of eosinophils by salmeterol and fluticasone. Eur Respir J 23 (2004) 511-517
6. Roth M., Johnson P.R., Rudiger J.J., King G.G., Ge Q., Burgess J.K., et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360 (2002) 1293-1299
7. Mak J.C., Hisada T., Salmon M., Barnes P.J., and Chung K.F. Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. Br J Pharmacol 135 (2002) 987-996
8. Pang L., and Knox A.J. Synergistic inhibition by β2-adrenoceptor agonists and corticosteroids on tumor necrosis factor-α-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol 23 (2000) 79-85
9. Nelson H.S., Chapman K.R., Pyke S.D., Johnson M., and Pritchard J.N. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 112 (2003) 29-36
10. Remington T.L., and Digiovine B. Long-acting beta-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Curr Opin Pulm Med 1 (2005) 74-78
11. Greening A.P., Ind P.W., Northfield M., and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 344 (1994) 219-224
12. Shrewsbury S., Pyke S., and Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 320 (2000) 1368-1373
13. Campbell D.A., and Robinson D.S. Cost advantages of combination asthma therapy. Treat Respir Med 3 (2004) 133-137
14. Garcia-Marcos L., Schuster A., and Cobos Barroso N. Inhaled corticosteroids plus long-acting B2-agonists as a combined therapy in asthma. Exp Opin Pharmacother 4 (2003) 23-39
15. Ringdal N., Chuchalin A., Chovan L., Tudoric N., Maggi E., and Whitehead P.J. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. Respir Med 96 (2002) 851-861
16. Coutts J.A.P., Gibson N.A., and Paton J.Y. Measuring compliance with inhaled medication in asthma. Arch Dis Child 67 (1992) 332-333
17. Chapman K.R., Walker L., Cluley S., and Fabbri L. Improving patient compliance with asthma therapy. Respir Med 94 (2000) 2-9
18. Kelloway J.S., Wyatt R., DeMarco J., and Adlis S. Effect of salmeterol on patients' adherence to their prescribed refills for inhaled corticosteroids. Ann Allergy Asthma Immunol 84 (2000) 324-328
19. Holt S., Masoli M., and Beasley R. Increasing compliance with inhaled corticosteroids through the use of combination therapy. J Allergy Clin Immunol 113 (2004) 219-220
20. Lotvall J. Combination therapy in asthma: fixed or variable dosing in different patients?. Curr Med Res Opin 20 (2004) 1711-1727
21. Nelson H.S. Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol 107 (2001) 398-416
22. Kuna P., and Kuprys I. Symbicort Turbuhaler: a new concept in asthma management. Int J Clin Pract 56 (2002) 797-803
23. Stoloff S.W., Stempel D.A., Meyer J., Stanford R.H., and Carranza Rosenzweig J.R. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 113 (2004) 245-251
24. Stempel D.A., Stoloff S.W., Carranza Rosenzweig J.R., Stanford R.H., Ryskina K.L., and Legorreta A.P. Adherence to asthma controller medication regimens. Respir Med 99 (2005) 1263-1267
25. Régie de l'assurance maladie du Québec (1997), Health Ministry, Goverment of Québec, Québec, Canada
26. World Health Organization. International classification of diseases: manual of the international statistical classification of diseases, injuries, and cause of death. 9th rev, publication #PHS 80-1260 (1977), World Health Organization, Geneva, Switzerland
27. Blais L., and Beauchesne M.-F. Use of inhaled corticosteroids following discharge from an emergency department for an acute exacerbation of asthma. Thorax 59 (2004) 943-947
28. Tamblyn R., Lavoie G., Petrella L., and Monette J. The use of prescription claims database in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48 (1995) 999-1009
29. Steiner J.F., and Prochazka A.V. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 50 (1997) 105-116
30. In: Kalbfleisch J.P., and Prentice R.L. (Eds). The statistical analysis of failure time data (1980), John Wiley & Sons, New York
31. Lee E.T. Nonparametric methods for comparing survival distributions. Statistical methods for survival data analysis. 2nd ed. Wiley series in probability and mathematical statistics: a probability and statistics section (1992), John Wiley & Sons, New York
32. Boulet L.P., Bai T.R., Becker A., Bérubé D., Beveridge R., Bowie D.M., et al. What is new since the last (1999) Canadian Asthma Consensus Guidelines?. Can Respir J 8 suppl A (2001) 5A-27A
33. Bukstein D.A., Henk H.J., and Luskin A.T. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther 23 (2001) 1589-1600
34. Stempel D.A., Mauskopf J., McLaughlin T., Yazdani C., and Stanford R.H. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 95 (2001) 227-234
35. Lynd L.D., Guh D.P., Pare P.D., and Anis A.H. Patterns of inhaled asthma medication use: a 3-year longitudinal analysis of prescription claims data from British Columbia, Canada. Chest 122 (2002) 1973-1981